Opt-X-Pense Kft
Opt-X-Pense Kft is recorded as a service provider in 33 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 33 trials · Latest update first
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies
Sponsor Merck KGaA
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multi-center, randomized, double-blind, placebo controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (VICTORION-PLAQUE)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Enrollment was restricted to participants who completed the 48-week treatment period in parent studies AROAPOC3-2001 or AROAPOC3-2002.
- Following a 22 November 2022 protocol amendment, participants receiving plozasiran 50 mg were changed to 25 mg every 3 months, and all active participants subsequently received 25 mg every 3 months for the remainder of the study.
- From 25 September 2024, participants could self-administer study drug using a prefilled syringe at the study site under investigator or designated-staff supervision.
These findings describe the trial, not the service provider’s performance or responsibility.
A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, double-blind study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIg) in participants with chronic inflammatory demyelinating polyneuropathy
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
Sponsor Verastem Inc.
- Start (EU)
- Latest update
- Estimated end
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
Sponsor Sutro Biopharma Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The trial enrolled 176 of the 600 subjects planned before early termination.
- Enrollment into the 4.3 mg/kg luveltamab tazevibulin dose group was discontinued after selection of the 5.2 mg/kg regimen with step-down to 4.3 mg/kg.
These findings describe the trial, not the service provider’s performance or responsibility.
A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheumatica (PMR)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A global, multicenter, randomized, double-blind, double-dummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney injury following cardiac surgery
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy who have completed a Novartis-sponsored iptacopan parent study in IgAN
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenance of response in participants with non-radiographic axial spondyloarthritis who achieved remission
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Opt-X-Pense Kft?
The 2026-10-09 snapshot links Opt-X-Pense Kft to 33 distinct CTIS trials. Recorded services include Patient compensation, patient reimbursement, Cost Reimbursement, Cost reimbursement services, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Opt-X-Pense Kft?
The most frequently recorded therapeutic areas are Immunology, Neurology, Solid Tumor Oncology, Cardiology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Opt-X-Pense Kft conducted?
The linked trials record locations in 26 countries, including Hungary, Spain, Italy, Poland, France. These are trial locations, not confirmed office locations or countries where Opt-X-Pense Kft delivered services.
What can this page tell me about Opt-X-Pense Kft's trial experience?
Browse 33 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Opt-X-Pense Kft. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Opt-X-Pense Kft.